AIDS/HIV, Antivirals, Dendritic Cells, Immune Antagonism, Infectious Disease, Inflammation, Influenza Virus, Interferon, Interferon Antagonists, Macrophage, Mucosal Immunology, Viruses and Virology
Immunology [IMM], Microbiology [MIC]
MS, University of Salamanca
PhD, Mount Sinai Graduate School (CUNY)
Best Faculty Mentor to Postdoctoral Fellows
Graduate School of Biomedical Sciences, Icahn School of Medicine at mount Sinai
Evasion of innate immunity by dengue virus (DENV)
Specific Clinical/Research Interests Mechanisms of evasion of immunity by dengue and influenza viruses; human immunology in viral infections. Generation of recombinant viruses.
Junior faculty: Irene Ramos, PhD. Sebastian Aguirre, PhD.
Postdoctoral Fellows: Ana Maestre, PhD, Rafael Fenutria-Aumesquet, PhD, Paula Lopez-Monteagudo, PhD.
Students: Edwin Carbajal, Jessica Pintado-Silva, Tong-Tong Zhu, Gabe Webb.
Research Personnel: Dabeiba Bernal-Rubio, Uma Potla
Past Members: Rebecca Hamlin PhD ,Kevin Maringer, PhD, Anthony Fredericks Ms, Sarah Pagni, PhD, Juan R. Rodriguez, PhD, Timothy Savage, MS, Phoenix Bell, MS.
Summary of Research Studies:
The main focuses of study in the Fernandez-Sesma laboratory are the interactions of important human pathogens with primary human immune cells.
Innate immunity to dengue virus and influenza virus
The Fernandez-Sesma laboratory studies innate immunity evasion by viruses of human health interest, such a dengue virus (DENV), influenza virus and other viruses, such as HIV. The main area of research in the Fernandez-Sesma laboratory is DENV, which is the most important mosquito transmitted virus in the world for which no vaccines or antiviral drugs are currently available. Additionally the Fernandez-Sesma laboratory investigates the interactions of influenza viruses with human immune cells and the strategies of innate immune evasion developed by important human pathogen.
For updated information please visit the Fernandez-Sesma lab website:
Maringer K, Fernandez-Sesma A. Message in a bottle: lessons learned from antagonism of STING signalling during RNA virus infection. Cytokine & growth factor reviews 2014 Aug;.
Rajsbaum R, Versteeg GA, Schmid S, Maestre AM, Belicha-Villanueva A, Martínez-Romero C, Patel JR, Morrison J, Pisanelli G, Miorin L, Laurent-Rolle M, Moulton HM, Stein DA, Fernandez-Sesma A, tenOever BR, García-Sastre A. Unanchored K48-linked polyubiquitin synthesized by the E3-ubiquitin ligase TRIM6 stimulates the interferon-IKKε kinase-mediated antiviral response. Immunity 2014 Jun; 40(6).
Manganaro L, Pache L, Herrmann T, Marlett J, Hwang Y, Murry J, Miorin L, Ting AT, König R, García-Sastre A, Bushman FD, Chanda SK, Young JA, Fernandez-Sesma A, Simon V. Tumor suppressor cylindromatosis (CYLD) controls HIV transcription in an NF-κB-dependent manner. Journal of virology 2014 Jul; 88(13).
Suthar MS, Aguirre S, Fernandez-Sesma A. Innate immune sensing of flaviviruses. PLoS pathogens 2013 Sep; 9(9).
Ramos I, Krammer F, Hai R, Aguilera D, Bernal-Rubio D, Steel J, García-Sastre A, Fernandez-Sesma A. H7N9 influenza viruses interact preferentially with α2,3-linked sialic acids and bind weakly to α2,6-linked sialic acids. The Journal of general virology 2013 Nov; 94(Pt 11).
Ramos I, Carnero E, Bernal-Rubio D, Seibert CW, Westera L, García-Sastre A, Fernandez-Sesma A. Contribution of double-stranded RNA and CPSF30 binding domains of influenza virus NS1 to the inhibition of type I interferon production and activation of human dendritic cells. Journal of virology 2013 Mar; 87(5).
Stefanidou M, Ramos I, Mas Casullo V, Trépanier JB, Rosenbaum S, Fernandez-Sesma A, Herold BC. Herpes simplex virus 2 (HSV-2) prevents dendritic cell maturation, induces apoptosis, and triggers release of proinflammatory cytokines: potential links to HSV-HIV synergy. Journal of virology 2013 Feb; 87(3).
Versteeg GA, Rajsbaum R, Sánchez-Aparicio MT, Maestre AM, Valdiviezo J, Shi M, Inn KS, Fernandez-Sesma A, Jung J, García-Sastre A. The E3-ligase TRIM family of proteins regulates signaling pathways triggered by innate immune pattern-recognition receptors. Immunity 2013 Feb; 38(2).
Morrison J, Laurent-Rolle M, Maestre AM, Rajsbaum R, Pisanelli G, Simon V, Mulder LC, Fernandez-Sesma A, García-Sastre A. Dengue virus co-opts UBR4 to degrade STAT2 and antagonize type I interferon signaling. PLoS pathogens 2013 Mar; 9(3).
Aguirre S, Maestre AM, Pagni S, Patel JR, Savage T, Gutman D, Maringer K, Bernal-Rubio D, Shabman RS, Simon V, Rodriguez-Madoz JR, Mulder LC, Barber GN, Fernandez-Sesma A. DENV Inhibits Type I IFN Production in Infected Cells by Cleaving Human STING.. PLoS Pathogens 2012 Oct; 8((10)): e1002934doi: 10.1371/journal.ppat.1002934. Epub 2012 Oct 4.
Chiang C, Engel A, Opaluch A, Ramos I, Maestre A, Secundino I, De Jesus P, Nguyen Q, Welch G, Bonamy G, Miraglia L, Orth A, Nizet V, Fernandez-Sesma A, Zhou Y, Barton G, Chanda S. Cofactors required for TLR7- and TLR9-dependent innate immune responses. . Cell Host and Microbe 2012 March 15; 11(3): 306-318.
Berger A, Sommer AF, Zwarg J, Hamdorf M, Welzel K, Esly N, Panitz S, Reuter A, Ramos I, Jatiani A, Mulder LC, Fernandez-Sesma A, Rutsch F, Simon V, König R, Flory E. SAMHD1-deficient CD14+ cells from individuals with Aicardi-Goutières syndrome are highly susceptible to HIV-1 infection. PLoS pathogens 2011 Dec; 7(12).
Varga ZT, Ramos I, Hai R, Schmolke M, García-Sastre A, Fernandez-Sesma A, Palese P. The influenza virus protein PB1-F2 inhibits the induction of type I interferon at the level of the MAVS adaptor protein. PLoS pathogens 2011 Jun; 7(6).
Ramos I, Bernal-Rubio D, Durham N, Belicha-Villanueva A, Lowen AC, Steel J, Fernandez-Sesma A. Effects of receptor binding specificity of avian influenza virus on the human innate immune response. Journal of virology 2011 May; 85(9).
Ashour J, Morrison J, Laurent-Rolle M, Belicha-Villanueva A, Plumlee CR, Bernal-Rubio D, Williams KL, Harris E, Fernandez-Sesma A, Schindler C, García-Sastre A. Mouse STAT2 restricts early dengue virus replication. Cell host & microbe 2010 Nov; 8(5).
Rodriguez-Madoz JR, Belicha-Villanueva A, Bernal-Rubio D, Ashour J, Ayllon J, Fernandez-Sesma A. Inhibition of type I IFN response in human dendritic cells by dengue virus infection requires catalytically active NS2B3 complex. J. Virol 2010 Oct; 84(19): 9760-9774.
Rodriguez-Madoz JR, Bernal-Rubio D, Kaminski D, Boyd K, Fernandez-Sesma A. Dengue virus inhibits the production of type I interferon in primary human dendritic cells. J. Virol 2010 May; 84(9): 4845-4850.
Haye K, Burmakina S, Moran T, García-Sastre A, Fernandez-Sesma A. The NS1 protein of a human influenza virus inhibits type I interferon production and the induction of antiviral responses in primary human dendritic and respiratory epithelial cells. Journal of virology 2009 Jul; 83(13).
Phipps-Yonas H, Seto J, Sealfon SC, Moran TM, Fernandez-Sesma A. Interferon- pretreatment of conventional and plasmacytoid human dendritic cells enhances their activation by influenza virus. PLoS Pathogens 2008 Oct 31; 4(10): e1000193.
Fernandez-Sesma A, Marukian S, Ebersole BJ, Kaminski D, Park MS, Yuen T, Sealfon SC, García-Sastre A, Moran TM. Influenza virus evades innate and adaptive immunity via the NS1 protein. Journal of virology 2006 Jul; 80(13).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Fernandez-Sesma has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.